E N D
1. Sickle cell disease in pregnancy A disease of tremendous clinical variability.
Clinical presentation seldom similar between any 2 individuals
5. Common clinical features Chronic haemolytic anaemia
The occurrence of episodic sometimes catastrophic complications
Typically unpredictable timing
6. adults People with sickle cell disease do not feel ill
Participate in regular activities (picture)
A few achieve high education and professional life
Survival into adulthood: still little assurance of continued wellbeing
7. Overtime Chronic haemolytic anaemia
Micro and macrovascular occlusion leading to chronic organ damage
Joint, Renal,cardiac,chest, cholethiasis
Retinopathy
8. Will I have problem conceiving? Fertility of women with sickle cell disease is generally unaffected
Except for the usual reason
Deferred age
Poor semen
Ovulatory disorders
Tubal disease
9. Which contraception should I use? No contraception is contra-indicated
Barrier methods: Easily available,safe,low PI
Progestogen only pill
Low dose combined oral contraceptives:Not contra-indicated
Depot progestogen
IUCD: Relative contra-indication thus Mirena instead
10. Pre-pregnancy counselling Combined clinic ideal
Partner testing/PND discussion
Pattern and frequency of crises
Previous CVA,infarction,VTE
Analgesic dependency
Transfusion history
Echocardiography
11. Prepregnancy counselling Immunization status
Antibiotics prophylaxis
Renal and hepatic status
Cardiopulmonary status
Eye status
High dose folic acid
Past Obstetric history
Individualized care plan
12. Pregnancy and hydroxyurea Safety remains unclear
Very large dose in animals shown to be teratogenic
To date no teratogenic effects reported in humans
Avoid pregnancy,
If become pregnant on it, stop medication and no need to terminate
13. Antenatal and neonatal screening: Aim To reduce infant morbidity and mortality from undiagnosed SCD
Alerting women to the possibility of having affected child
Counseling about the condition
To offer the option of prenatal diagnosis
Occasionally picks up new and milder forms
14. Neonatal screening: Where are we at? Newborns-Universal screening by March 2005
Guthrie test at 5-8
Fully implemented in London since Sept 2003
London prevalence of SCD 1:750
Alison Streetly(Programme director)
15. Antenatal screening: Where are we at? Two phase roll out
Full coverage by March
Universal thalasaemia screening
Sickle cell high or low prevalence
Family origin question(Dyson et al,2006)
Midwives role pivotal in the process
Aliosn Streetly (program director),2006
16. Suitability for PGD Fertility problems, objection to abortions, or history of multiply affected babies
Family or personal history of Mendelian disorder or chromosomal disorders
PGD License and technique for disorder
Payment - either personal or local PCT/HA
17. Limitations of PGD Not suitable for majority of couples
Stressful, time-consuming, requiring high level of commitment
Only 15-20% of PGD cycles result in babies
Reduces risk rather than eliminates - roughly 5% failure rate, due to limitation of single-cell analysis
18. Non-invasive Fetal Diagnosis Isolation of fetal DNA from maternal blood
small amounts of free fetal DNA present in maternal plasma
technically easy to concentrate and analyse by PCR
limited application - dominant diseases, screening for paternal contributions to compound heterozygous states
currently being developed at KCH for HbSC
19. Maternal and fetal risk Maternal
Anaemia
Infection(UTI,Chest,puerperal sepsis)
Crises
PET
Thromboembolism
Fetal
Miscarraige
Intra-uterine growth restriction
Increased risk of prematurity
Increased risk of fetal distress
20. Antenatal care To give appropriate care to ensure healthy mother and baby
Avoidance and early treatment of crises
Low threshold for admission if unwell
Screening of partner and offer prenatal diagnosis where indicated
21. Booking Early booking between 6 and 12 weeks is recommended
Early dating scan essential
Ensure taking folic acid and penicillin prophylaxis
Booking investigations +PET bloods
22. Antenatal sickle clinic(ASC) Once a month Joint clinic with Haematologist,Specialist nurse and high risk midwives
Once a month review by high risk midwife
Access to antenatal and haematology day unit 7 days a week
23. ASC clinic At 20 week scan uterine artery dopplers performed
4 weekly growth scans
Delivery between 38-40 weeks unless obstetric indication otherwise
24. Reasons for admission Sickle cell crises and pain
Blood transfusion
Shortness of breath
Pre-eclampsia
Induction of labour
Infection
Labour
25. Sickle crises:Precipitating factors Infection
Fever
Dehydration
Cold
Prolonged labour
operative delivery
26. Management Keep warm and hydrated
Maintain strict fluid balance chart
If initial saturation below 94%, give humidified Oxygen 4l
Do blood gases
Appropriate pain relief
Infection screen
Physiotherapy if evidence of chest complication
27. Blood transfusion Only if clinically indicated
On going high transfusion regime
Multiple pregnancy
Complicated pregnancy
Recurrent crises
28. Umbilical cord blood banking UK national cord blood bank currently stores over 7000 units of cord blood samples
Donated altruistically for non-directed use
Under the auspices of National Blood service
Currently seven other private banks in the UK
29. Umbilical cord banking Dual public-private approach
1 in 10 000 to 1 in 20 000 likelihood for personal use
Used in preference to Bone marrow
Fewer complications,easier availability,
higher matching success esp BME. Limitations:cells from 1 cord insufficient
Defect already present in the child own cord cells
Shows great promise
30. Pitfalls in management Haemoglobin SC disease may not run a benign course in pregnancy
Prompt diagnosis of crises saves lives
Acute chest syndrome may develop from an initial uncomplicated crises
Signs of ACS can be non-specific
31. Acute chest syndrome Pulmonary crises-infarction+/-infection
Adults are often afebrile
Lung examination can be normal but progressive hypoxia
CXR: Lower lobe involvement
32. Management of Acute chest syndrome Involve haematologist and anaesthetist early
Blood should be leucocyte depleted and phenotype specific
Exchange transfusion
Antibiotics
Therapeutic clexane
Oxygen and physiotherapy
33. Sudden death in sickle cell disease Recognised in SS, SC and AS
Postmorten evidence
Intravascular plugs of sickle RBCS
Extensive fibromascular dysplasia
Abnormal fibrosis through out conducting system
Lethal cardiac electrical instability
34. Summary Sickle cell disease is an inherited disorder of varying clinical severity with potentially serious complications
Pregnant woman with sickle cell disease is at considerable risk of morbidity and mortality and perinatal mortality rates are high
35. Summary Expert knowledge of the condition, proper crises intervention and appropriate management can alleviate some of these complications